Experienced in Multicentric Castleman Disease (MCD)

Dr. David F. Claxton

Hematology Oncology | Hematology | Oncology
500 University Dr, 
Hershey, PA 
41 Years of Experience
Experienced in Multicentric Castleman Disease (MCD)
500 University Dr, 
Hershey, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Claxton is a Hematologist Oncology specialist and a Hematologist in Hershey, Pennsylvania. Dr. Claxton has been practicing medicine for over 41 years and is rated as an Experienced provider by MediFind in the treatment of Multicentric Castleman Disease (MCD). His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Childhood Acute Myeloid Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 111 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in PA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

500 University Dr, Hershey, PA 17033

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase I Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (RR-AML)
Phase I Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (RR-AML)
Enrollment Status: Enrolling_by_invitation
Publish Date: October 07, 2025
Intervention Type: Drug
Study Drug: Ceramide NanoLiposome
Study Phase: Phase 1
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine or Vincristine Sulfate in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia
A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine or Vincristine Sulfate in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Drug, Procedure
Study Drugs: Venetoclax, Liposomal Vincristine
Study Phase: Phase 1/Phase 2
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2025
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin, Daunorubicin, Cytarabine
Study Phase: Phase 2
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug, Other, Procedure
Study Drugs: Clofarabine, Daunorubicin, Cytarabine, Decitabine
Study Phase: Phase 3
A Randomized Phase 2 Study of Oral Sapacitabine in Elderly Patients With Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndromes
A Randomized Phase 2 Study of Oral Sapacitabine in Elderly Patients With Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndromes
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
View 7 Less Clinical Trials

111 Total Publications

Acid ceramidase inhibition enhances BCL-2 targeting in venetoclax-resistant acute myeloid leukemia via a cytotoxic integrated stress response.
Acid ceramidase inhibition enhances BCL-2 targeting in venetoclax-resistant acute myeloid leukemia via a cytotoxic integrated stress response.
Journal: bioRxiv : the preprint server for biology
Published: June 12, 2025
Similar Doctors
Experienced in Multicentric Castleman Disease (MCD)
Dr. W C. Ehmann
Hematology Oncology | Hematology | Oncology
Experienced in Multicentric Castleman Disease (MCD)
Dr. W C. Ehmann
Hematology Oncology | Hematology | Oncology

The Milton S Hershey Medical Center Physicians Group

500 University Dr, 
Hershey, PA 
 (0.1 miles away)
717-531-8395
Languages Spoken:
English
See accepted insurances

W Ehmann is a Hematologist Oncology specialist and a Hematologist in Hershey, Pennsylvania. Dr. Ehmann is rated as a Distinguished provider by MediFind in the treatment of Multicentric Castleman Disease (MCD). His top areas of expertise are Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.

Experienced in Multicentric Castleman Disease (MCD)
Dr. Meide D. Lu
Hematology Oncology | Hematology | Oncology
Experienced in Multicentric Castleman Disease (MCD)
Dr. Meide D. Lu
Hematology Oncology | Hematology | Oncology
S 6th Avenue & Spruce Street, N-ground Trhmc Regional Cancer Center, 
West Reading, PA 
 (38.5 miles away)
610-374-4404
Languages Spoken:
English
See accepted insurances

Meide Lu is a Hematologist Oncology specialist and a Hematologist in West Reading, Pennsylvania. Dr. Lu is rated as a Distinguished provider by MediFind in the treatment of Multicentric Castleman Disease (MCD). His top areas of expertise are Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, Lung Cancer, and ALK-Positive Non-Small Cell Lung Cancer.

Experienced in Multicentric Castleman Disease (MCD)
Dr. Chanh T. Huynh
Hematology Oncology | Hematology | Oncology
Experienced in Multicentric Castleman Disease (MCD)
Dr. Chanh T. Huynh
Hematology Oncology | Hematology | Oncology

Cancer Care Associates Of York, Inc.

25 Monument Rd, Suite 294, 
York, PA 
 (23.5 miles away)
717-741-9229
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Chanh Huynh is a Hematologist Oncology specialist and a Hematologist in York, Pennsylvania. Dr. Huynh is rated as a Distinguished provider by MediFind in the treatment of Multicentric Castleman Disease (MCD). His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Colorectal Cancer, Lynch Syndrome, Familial Colorectal Cancer, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Claxton's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 17 Advanced Conditions
View All 38 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile